BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitor
Retrieved on:
Tuesday, November 7, 2023
Society for Immunotherapy of Cancer, Merkel-cell carcinoma, Radiation, PD-L1, MD–PhD, NSCLC, AACR, Trial of the century, PD, RT, Nivolumab, DCR, Pembrolizumab, Monroe Dunaway Anderson, PD-1, RCC, HIV disease progression rates, PI, SITC, Immunotherapy, SD, Hodgkin lymphoma, Solar cycle 1, Drug discovery, Cancer, Webcast, RECIST, Solar cycle 2, University, Society, Monocyte, MD Anderson Cancer Center, Patient, Toxicity, PR, Medical device, Pharmaceutical industry, Vaccine, Medical imaging, Palladium, SCCHN, IO, Plinabulin
Based on preclinical models, where plinabulin plus radiation and anti-PD-1 antibody enhances dendritic cell (DC) activation, T-cell proliferation, and abscopal effect, a clinical study was initiated to test these findings.
Key Points:
- Based on preclinical models, where plinabulin plus radiation and anti-PD-1 antibody enhances dendritic cell (DC) activation, T-cell proliferation, and abscopal effect, a clinical study was initiated to test these findings.
- 11 out of 14 patients eligible for efficacy assessment per RECIST criteria and had measurable target lesion responses in the non-irradiated tumor lesion.
- Please reference conference title: Clinical Significance of Plinabulin SITC Presentation with PI Dr. Steven Lin from MD Anderson.
- A live webcast will be available on BeyondSpring’s website at www.beyondspringpharma.com under “Events & Presentations” in the Investors section.